ALNY
Alnylam Pharmaceuticals, Inc.
NMS
$286.12
-9.51
(-3.22%)
Pullback · -1.16σ
Quarterly financials
last 6 quarters| Quarter | Revenue | Gross profit | Op income | Net income | Free cash flow | Gross % | Op % | Net % |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $1.17B | $956.1M | $268.6M | $206.0M | $48.7M | 81.9% | 23.0% | 17.6% |
| 2025-12-31 | $1.10B | $829.3M | $131.7M | $186.4M | $140.3M | 75.6% | 12.0% | 17.0% |
| 2025-09-30 | $1.25B | $1.05B | $368.0M | $251.1M | $313.0M | 84.0% | 29.5% | 20.1% |
| 2025-06-30 | $773.7M | $630.7M | $-16.2M | $-66.3M | $141.4M | 81.5% | -2.1% | -8.6% |
| 2025-03-31 | $594.2M | $523.1M | $18.1M | $-18.3M | $-129.3M | 88.0% | 3.0% | -3.1% |
| 2024-12-31 | $nan | $nan | $nan | $nan | $nan | nan% | nan% | nan% |